Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

Bibliographic Details
Main Authors: Machiels, Jean-Pascal H, Licitra, Lisa F, Haddad, Robert I, Tahara, Makoto, Cohen, Ezra EW
Format: Online
Language:English
Published: BioMed Central 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079914/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4079914/

Similar Items